Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial.

Donno V, Neves AR, García-Martinez S, Rodriguez I, Polyzos NP

Fertility and sterility16 Sept 2025Cited by 1 (Europe PMC)

PMID40967454DOI10.1016/j.fertnstert.2025.09.016PepBankPUB-40967454

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialSafety outcome
In women undergoing fertility preservation, no ovarian hyperstimulation syndrome occurred with triptorelin alone.
In plain wordsIn women undergoing fertility preservation, no ovarian hyperstimulation syndrome occurred with triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOvarian hyperstimulation syndrome with triptorelin alone
Study
n = 54
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mgAs given in this study (human).
Source sentences
Summary
Notably, neither group exhibited any case of ovarian hyperstimulation syndrome.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
Report a problemFND-4096745407

Studies that did not test the peptide alone7

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, triptorelin plus hCG and triptorelin alone did not differ significantly in mature oocytes retrieved.
In plain wordsIn women undergoing fertility preservation, mature oocyte counts were similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMature oocytes retrieved
Study
n = 109
Comparator
triptorelin alone
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
MII oocytes retrieved
7.31 oocytes
dual trigger (triptorelin + hCG)
MII oocytes retrieved
7.94 oocytes
GnRH-a alone (triptorelin)
Estimated mean difference, MII oocytes
−0.64 oocytes
dual trigger minus GnRH-a
95% CI of mean difference, MII oocytes
−2.07 to 0.8 oocytes
dual trigger minus GnRH-a
Source sentences
Summary
No statistically significant differences were found regarding the total number of oocytes nor MII oocytes retrieved between the dual trigger and GnRH-a groups (9.22 ± 5.11 vs. 9.56 ± 5.16 [estimated mean difference, -0.34 {95% confidence interval, -2.29 to 1.61}] and 7.31 ± 4.63 vs. 7.94 ± 4.39 grou…
5 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
Summary · context
The primary endpoint was the number of metaphase II (MII) oocytes retrieved after final oocyte maturation with dual trigger and GnRH-a trigger in patients undergoing elective fertility preservation.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745402
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, triptorelin plus hCG and triptorelin alone did not differ significantly in total oocytes retrieved.
In plain wordsIn women undergoing fertility preservation, total oocyte counts were similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTotal oocytes retrieved
Study
n = 109
Comparator
triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Total oocytes retrieved
9.22 oocytes
dual trigger (triptorelin + hCG)
Total oocytes retrieved
9.56 oocytes
GnRH-a alone (triptorelin)
Estimated mean difference, total oocytes
−0.34 oocytes
dual trigger minus GnRH-a
95% CI of mean difference, total oocytes
−2.29 to 1.61 oocytes
dual trigger minus GnRH-a
Source sentences
Summary
No statistically significant differences were found regarding the total number of oocytes nor MII oocytes retrieved between the dual trigger and GnRH-a groups (9.22 ± 5.11 vs. 9.56 ± 5.16 [estimated mean difference, -0.34 {95% confidence interval, -2.29 to 1.61}] and 7.31 ± 4.63 vs. 7.94 ± 4.39 grou…
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745401
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, estradiol after triggering did not differ significantly between triptorelin plus hCG and triptorelin alone.
In plain wordsIn women undergoing fertility preservation, estradiol was similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEstradiol after trigger
Study
n = 109
Comparator
triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745403
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, progesterone after triggering did not differ significantly between triptorelin plus hCG and triptorelin alone.
In plain wordsIn women undergoing fertility preservation, progesterone was similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeProgesterone after trigger
Study
n = 109
Comparator
triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745404
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, luteinizing hormone after triggering did not differ significantly between triptorelin plus hCG and triptorelin alone.
In plain wordsIn women undergoing fertility preservation, luteinizing hormone was similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLuteinizing hormone after trigger
Study
n = 109
Comparator
triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745405
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women undergoing fertility preservation, follicle-stimulating hormone after triggering did not differ significantly between triptorelin plus hCG and triptorelin alone.
In plain wordsIn women undergoing fertility preservation, follicle-stimulating hormone was similar with triptorelin plus hCG and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFollicle-stimulating hormone after trigger
Study
n = 109
Comparator
triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745406
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In women undergoing fertility preservation, no ovarian hyperstimulation syndrome occurred with triptorelin plus hCG.
In plain wordsIn women undergoing fertility preservation, no ovarian hyperstimulation syndrome occurred with triptorelin plus hCG.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOvarian hyperstimulation syndrome with dual trigger
Study
n = 55
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
Notably, neither group exhibited any case of ovarian hyperstimulation syndrome.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, controlled, single-center, superiority clinical trial.
Summary · context
Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles.
Summary · context
As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg).
Summary · context
Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-4096745408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.